|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
30
|
|
pubmed:dateCreated |
2005-11-29
|
|
pubmed:abstractText |
To compare the efficacy of combination regiments of taxol given weekly plus carboplatin and taxol given every three weeks plus carboplatin. To observe the toxicity of the two regiments. To observe the two-year survival rate in the two groups.
|
|
pubmed:language |
chi
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0376-2491
|
|
pubmed:author |
pubmed-author:ChenYi-leYL,
pubmed-author:China Gynecological Oncology Group (CGOG),
pubmed-author:DeanA CAC,
pubmed-author:FengYou-jiYJ,
pubmed-author:HoltL BLB,
pubmed-author:KongBei-huaBH,
pubmed-author:LangJing-heJH,
pubmed-author:LeiSongS,
pubmed-author:LiMeng-daMD,
pubmed-author:LiZi-tingZT,
pubmed-author:LuiJi-hongJH,
pubmed-author:PengZhi-lanZL,
pubmed-author:ShenKengK,
pubmed-author:WuLing-yingLY,
pubmed-author:WuMingM,
pubmed-author:XXX,
pubmed-author:XieXingX
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2099-103
|
|
pubmed:dateRevised |
2010-6-4
|
|
pubmed:meshHeading |
pubmed-meshheading:16313817-Adult,
pubmed-meshheading:16313817-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16313817-Carboplatin,
pubmed-meshheading:16313817-Cystadenocarcinoma, Mucinous,
pubmed-meshheading:16313817-Cystadenocarcinoma, Serous,
pubmed-meshheading:16313817-Drug Administration Schedule,
pubmed-meshheading:16313817-Female,
pubmed-meshheading:16313817-Humans,
pubmed-meshheading:16313817-Middle Aged,
pubmed-meshheading:16313817-Ovarian Neoplasms,
pubmed-meshheading:16313817-Paclitaxel,
pubmed-meshheading:16313817-Prospective Studies,
pubmed-meshheading:16313817-Proteins,
pubmed-meshheading:16313817-Survival Analysis
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
[A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer].
|
|
pubmed:affiliation |
shenkeng@vip.sina.com
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Randomized Controlled Trial,
Multicenter Study
|
